Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate

被引：0
|
作者：
Ezziddin, S. [1 ]
Sabet, A. [1 ]
Heinemann, F. [1 ]
Yong-Hing, C. [2 ]
Ahmadzadehfar, H. [1 ]
Guhlke, S. [1 ]
Hoeller, T. [1 ]
Willinek, W. [1 ]
Boy, C. [3 ]
Biersack, H. [1 ]
机构：
[1] Univ Hosp, Bonn, Germany
[2] Univ British Columbia Hosp, Vancouver, BC, Canada
[3] Univ Hosp, Essen, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S139 / S139
页数：1
相关论文
共 50 条
  • [21] Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
    Amir Sabet
    Kristina Dautzenberg
    Torjan Haslerud
    Anas Aouf
    Amin Sabet
    Birgit Simon
    Karin Mayer
    Hans-Jürgen Biersack
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1238 - 1246
  • [22] Peptide receptor radionuclide therapy of neuroendocrine tumours with 177Lu-octreotate: first experience in a French Canadian centre
    Del Prete, M.
    Buteau, F. A.
    Beauregard, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S725 - S725
  • [23] Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
    van Essen, Martijn
    Krenning, Eric P.
    Bakker, Willem H.
    de Herder, Wouter W.
    van Aken, Maarten O.
    Kwekkeboom, Dik J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (08) : 1219 - 1227
  • [24] Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
    Martijn van Essen
    Eric P. Krenning
    Willem H. Bakker
    Wouter W. de Herder
    Maarten O. van Aken
    Dik J. Kwekkeboom
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 1219 - 1227
  • [25] Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
    Samer Ezziddin
    Feras Khalaf
    Maria Vanezi
    Torjan Haslerud
    Karin Mayer
    Abdullah Al Zreiqat
    Winfried Willinek
    Hans-Jürgen Biersack
    Amir Sabet
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 925 - 933
  • [26] Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment
    Hamiditabar, Mohammadali
    Ali, Muzammil
    Roys, Joseph
    Wolin, Edward M.
    O'Dorisio, Thomas M.
    Ranganathan, David
    Tworowska, Izabela
    Strosberg, Jonathan R.
    Delpassand, Ebrahim S.
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 436 - 443
  • [27] Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas
    Iliuta, Ioan-Andrei
    Beauregard, Jean-Mathieu
    Couture, Felix
    Douville, Pierre
    Mac-Way, Fabrice
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (09) : E448 - E450
  • [28] Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
    Ezziddin, Samer
    Khalaf, Feras
    Vanezi, Maria
    Haslerud, Torjan
    Mayer, Karin
    Al Zreiqat, Abdullah
    Willinek, Winfried
    Biersack, Hans-Juergen
    Sabet, Amir
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) : 925 - 933
  • [29] Long-term survival and toxicity in patients with neuroendocrine tumors treated with Lu-177-octreotate peptide radionuclide therapy
    Kennedy, Kim R.
    Turner, John Harvey
    MacDonald, William B. G.
    Claringbold, Phillip G.
    Boardman, Glenn
    Ransom, David T.
    CANCER, 2022, 128 (11) : 2182 - 2192
  • [30] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Michela Del Prete
    François-Alexandre Buteau
    Frédéric Arsenault
    Nassim Saighi
    Louis-Olivier Bouchard
    Alexis Beaulieu
    Jean-Mathieu Beauregard
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 728 - 742
12345